2019-07002. National Institute on Drug Abuse; Notice of Closed Meeting  

  • Start Preamble

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

    The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Medication Discovery Using Rat Models of Relapse (8949).

    Date: May 16, 2019.

    Time: 11:00 a.m. to 1:00 p.m.

    Agenda: To review and evaluate contract proposals.

    Place: National Institutes of Health, Neuroscience Center Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

    Contact Person: Lyle Furr, Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892-9550, (301) 827-5702, lf33c.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Analytical Chemistry & Stability Testing of Treatment Drugs (8950).

    Date: May 21, 2019.

    Time: 11:00 a.m. to 1:00 p.m.

    Agenda: To review and evaluate contract proposals.

    Place: National Institutes of Health, Neuroscience Center Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).

    Contact Person: Lyle Furr, Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892-9550, (301) 827-5702, lf33c.nih.gov.

    (Catalogue of Federal Domestic Assistance Program No.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

    Start Signature

    Dated: April 4, 2019.

    Natasha M. Copeland,

    Program Analyst, Office of Federal Advisory Committee Policy.

    End Signature End Preamble

    [FR Doc. 2019-07002 Filed 4-8-19; 8:45 am]

    BILLING CODE 4140-01-P

Document Information

Published:
04/09/2019
Department:
Health and Human Services Department
Agency:
National Institutes of Health
EntryType:
Notice
Document Number:
2019-07002
Dates:
May 16, 2019.
Pages:
14123-14123 (1 pages)
SectionNoes:
PDF File:
2019-07002.pdf